Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Medtronic
Mallinckrodt
Johnson and Johnson
McKesson
AstraZeneca
Merck

Last Updated: November 22, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,367,333

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 7,367,333 protect, and when does it expire?

Patent 7,367,333 protects SYMBICORT and is included in one NDA.

Protection for SYMBICORT has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has fifty-one patent family members in twenty-four countries.

Summary for Patent: 7,367,333
Title:Inhalation device
Abstract:Actuator for an inhaler for delivering medicament by inhalation. The actuator includes a main body having a tubular member for receiving a canister containing medicament and having a valve stem extending therefrom, and an outlet assembly, as a part formed separately of the main body, having a mouthpiece for guiding medicament to the mouth of a user and a nozzle block for receiving the valve stem of the canister and delivering medicament from the canister into the mouthpiece. At least a part of the outlet assembly is configured so as to deform and optionally break on withdrawal of the outlet assembly from the main body so as to prevent re-use of the outlet assembly.
Inventor(s): Hodson; Darren (Shropshire, GB), Rasmussen; Jorgen (Struer, DK)
Assignee: AstraZene a AB (Sodertalje, SE)
Application Number:10/698,950
Patent Claim Types:
see list of patent claims
Delivery; Device;

Drugs Protected by US Patent 7,367,333

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Astrazeneca SYMBICORT budesonide; formoterol fumarate dihydrate AEROSOL, METERED;INHALATION 021929-001 Jul 21, 2006 RX Yes Yes   Start Trial   Start Trial   Start Trial
Astrazeneca SYMBICORT budesonide; formoterol fumarate dihydrate AEROSOL, METERED;INHALATION 021929-002 Jul 21, 2006 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,367,333

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Sweden9704185Nov 14, 1997

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Dow
McKinsey
AstraZeneca
Merck
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.